Voyager Therapeutics Stands Out As a High Risk, High-Reward Player in Neurological Cell Gene Therapy

Photo of author
Written By Jackson Hartwell

Voyager Therapeutics Inc. has captured the attention of the biotechnology sector with its innovative approach to treating neurological disorders. 

Despite the inherent volatility associated with biotech investments, Voyager’s significant advancements in TRACER capsid technology and strategic partnerships position it as a speculative but potentially rewarding buy for long-term investors.

Financial and Market Overview

Recent market activities reflect Voyager’s volatile share price, which experienced a sharp decline of -7.5% following its earnings release on February 28th, 2024, before rallying 15.87% and then trending downwards again. As of the latest update, the share price stands at USD 9.23. 

Credit: DepositPhotos

This volatility is not unusual for biotech companies, especially those like Voyager, which are yet to commercialize their products. The company’s financial health is bolstered by its high current ratio and extended cash runway into 2026, indicating a low risk of near-term dilution.

Read More: Sunnova Energy’s Entanglement in Grueling Battle Over Loan Agreement Continues 

TRACER Capsid Technology

At the core of Voyager’s promise is its TRACER capsid technology, capable of delivering therapeutic molecules across the blood-brain barrier (BBB) to neuron and glial cells. 

This breakthrough has the potential to revolutionize treatments for Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS), among others. 

The technology’s ability to facilitate minimally invasive systemic intravenous injections has attracted multimillion-dollar collaborations with pharmaceutical giants, including Novartis, Neurocrine, Pfizer, and AstraZeneca.

Financial Performance and Strategic Partnerships

Voyager’s FY2023 financial results highlight the company’s reliance on its TRACER-AAV capsid discovery platform for revenue generation through strategic partnerships. 

Despite not having commercialized products, Voyager managed to report a revenue of $250 million for FY2023, a significant increase from the previous year, largely due to its deals with Novartis and Neurocrine. 

The extended cash runway and expected reimbursement for development costs under collaborations provide financial stability and support for ongoing clinical trials.

Also Read: This Company is Innovating in The Online Learning Landscape – Is It Worth Your Investment?

Market Sentiment and Valuation

Despite high short interest, the overall market sentiment towards Voyager remains robust, driven by insider buying and significant institutional investment. 

The company’s stock momentum significantly outperforms the broader market, with a notable increase in valuation following the announcement of the Novartis deal in early January. 

However, the speculative nature of Voyager’s stock requires investors to weigh the potential for high returns against the inherent risks of the biotech sector.

Risk Considerations and Clinical Trials

Voyager’s ambitious clinical trial schedule for its advanced programs, targeting mid-2024 to 2025, underscores the potential for groundbreaking treatments. However, the company’s operational losses and reliance on the yet-to-be-clinically validated TRACER technology pose risks. 

Success in upcoming trials and regulatory approval is crucial for transforming Voyager’s scientific potential into commercial success.

Future Prospects and Investor Outlook

Voyager’s strategic focus on developing cell and gene therapies for neurological conditions, supported by its unique TRACER platform and strong pharmaceutical partnerships, presents a compelling case for long-term investment. 

Credit: DepositPhotos

While the road ahead is fraught with challenges typical of the biotech sector, Voyager’s innovative approach and financial resilience offer a tantalizing glimpse into the future of neurological treatment. 

As clinical trials progress, Voyager stands on the brink of potentially delivering substantial returns to investors willing to navigate the high-risk landscape of biotechnology.

Read Next: Is Golar LNG a Buy After its Most Recent Earnings Beat?


You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at; the Financial Industry Regulatory Authority (the "FINRA") at, and relevant State Securities Administrator website and the OTC Markets website at The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: and

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.